NASDAQ:AXGNAxoGen Stock Price, Forecast & News

AxoGen's stock was trading at $10.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AXGN stock has increased by 5.3% and is now trading at $11.27.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AxoGen.

AxoGen is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for AxoGen.

AxoGen, Inc (NASDAQ:AXGN) released its quarterly earnings results on Wednesday, August, 5th. The medical equipment provider reported ($0.20) EPS for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.13. AxoGen had a negative return on equity of 21.62% and a negative net margin of 28.04%.
View AxoGen's earnings history.

AxoGen updated its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $21 million, compared to the consensus revenue estimate of $11.67 million.

4 brokers have issued 12 month price targets for AxoGen's stock. Their forecasts range from $12.00 to $21.00. On average, they anticipate AxoGen's share price to reach $16.13 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price.
View analysts' price targets for AxoGen.

Media stories about AXGN stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AxoGen earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about AxoGen.

AxoGen saw a decrease in short interest in May. As of May 15th, there was short interest totaling 1,490,000 shares, a decrease of 14.4% from the April 30th total of 1,740,000 shares. Based on an average daily trading volume, of 588,000 shares, the days-to-cover ratio is currently 2.5 days. Approximately 4.1% of the company's shares are short sold.
View AxoGen's Short Interest.

Some companies that are related to AxoGen include InMode (INMD), BioLife Solutions (BLFS), Natus Medical (NTUS), Zynex (ZYXI), TransMedics Group (TMDX), Viewray (VRAY), Semler Scientific (SMLR), Stereotaxis (STXS), Cutera (CUTR), BioSig Technologies (BSGM), Fonar (FONR), Edap Tms (EDAP), Soleno Therapeutics (SLNO), electroCore (ECOR) and Fc Global Realty (FCRE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Intel (INTC), Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Bank of America (BAC), Exelixis (EXEL) and AbbVie (ABBV).

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (2.50%), Bank of New York Mellon Corp (1.26%), Granite Investment Partners LLC (1.01%), Federated Hermes Inc. (0.89%), Bank of Montreal Can (0.89%) and Granite Point Capital Management L.P. (0.85%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan and Quentin S Blackford.
View institutional ownership trends for AxoGen.

AXGN stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, William Blair Investment Management LLC, Goldman Sachs Group Inc., UBS Group AG, and New York State Common Retirement Fund.
View insider buying and selling activity for AxoGen.

AXGN stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Granite Point Capital Management L.P., Assenagon Asset Management S.A., Bank of Montreal Can, Tocqueville Asset Management L.P., Granite Investment Partners LLC, Marshall Wace LLP, and Aigen Investment Management LP. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej, and Quentin S Blackford.
View insider buying and selling activity for AxoGen.

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXGN stock can currently be purchased for approximately $11.27.

AxoGen has a market capitalization of $451.75 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-29,140,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

The official website for AxoGen is www.axogeninc.com.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]